PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Adding Value to Nature-Identical Therapies Portfolio
- Stock split, CSE listing show evidence of company’s shareholder commitment
- PreveCeutical balancing need for unique profit-building intellectual property with mission to offer affordable products to patients
- Manufacturer agreement, licensed shipments advance CBD therapy research
- Alternative medicines market valued at more than $40 billion
PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) dedication to developing preventative medical therapies based on the identified health benefits of natural substances in controllable formulations that are both affordable to consumers and potentially profitable to investors is on display in the company’s recent shareholder-approved forward stock split and the opening of trade on the Canadian Securities Exchange.
PreveCeutical’s shares began trading on the CSE on an “ex-distribution” basis on May 23 (http://nnw.fm/Ll6nF), the day before the recording date for the stock split, which was set at a five new common shares for each one existing common share basis (http://nnw.fm/4nGst).
“We believe the Stock Split demonstrates the Company’s continued commitment to broaden its shareholder base and we anticipate that the Stock Split will make PreveCeutical’s securities more accessible to investors and enhance liquidity for shareholders,” CEO, president and board Chairman Stephen Van Deventer stated in announcing the dates.
PreveCeutical has five research and development programs under way to target type 2 diabetes and obesity, pain relief in a non-addicting manner, mild traumatic brain injury in athletes, cancer and various other ailments. PreveCeutical also sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website (www.CELLB9.com).
“When we’ve developed proof-of-concept on any of these projects, we intend to partner with other companies who will fund clinical trials,” Van Deventer said in a May interview with Financial Post (http://nnw.fm/sF6QS).
Chief Research Officer Dr. Harry Parekh, who leads the drug/gene delivery group at PreveCeutical’s University of Queensland’s research partner Pharmacy Australia Centre of Excellence (“PACE”), who developed the Sol-gel drug delivery mechanism employed by PreveCeutical as well as the technology that stabilizes molecules to make them viable as the company’s therapeutic products. Sol-gel refers to a water-soluble gel formulation that can be used to transport a drug into the body via the nasal cavity, for example, where it is expected to gain direct access to the brain and thus enhance its effectiveness.
“I’ve been courted by a number of entities to work on research projects in relation to my platforms and it’s fair to say that big pharma is not a good match for me,” Parekh told Financial Post, adding that PreveCeutical proved to be a good partner for him because “they understood my mission to translate technologies to medications in a moral and ethical fashion, with the goal of drastically reducing costs for end users … (while recognizing) the fundamental necessity of developing exploitable IP,” or intellectual property, for the benefit of investors.
One of PreveCeutical’s key efforts is to use Sol-gel to make cannabidiol (CBD) optimally bioavailable to patients dealing with pain, inflammation, seizures and neurological issues such as anxiety. CBD is a non-psychoactive product of the cannabis plant gaining wide use as a food additive in homeopathic consumables, but the Sol-gel formulation would allow the CBD to get to work without having to run through the potentially destructive gauntlet of the digestive system’s organs. PreveCeutical recently announced a non-disclosure agreement with a leading drug delivery device manufacturer to work with the Sol-gels (http://nnw.fm/PGsc7), as well as the second successful licensed international transport of dried cannabis materials for the PACE center’s research on the Sol-gels (http://nnw.fm/z3ZAn).
Grandview Research found that the market for alternative medicines was valued at $40.3 billion at the time of its study three years ago. The report found that 60 percent of the world’s population uses some type of traditional or non-conventional medicine, and a separate report by The National Center for Disease Control found that 20 percent of the United States’ population uses alternative therapies, as noted in a Crystal Equity Research Report on PreveCeutical (http://nnw.fm/nB5PL).
Crystal Equity’s report concluded that, “We expect 2018 will be a significant year for PreveCeutical Medical with numerous value-driving catalysts unfolding.”
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Stock split, CSE listing show evidence of company’s shareholder commitment
- PreveCeutical balancing need for unique profit-building intellectual property with mission to offer affordable products to patients
- Manufacturer agreement, licensed shipments advance CBD therapy research
- Alternative medicines market valued at more than $40 billion
PreveCeutical Medical Inc.’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) dedication to developing preventative medical therapies based on the identified health benefits of natural substances in controllable formulations that are both affordable to consumers and potentially profitable to investors is on display in the company’s recent shareholder-approved forward stock split and the opening of trade on the Canadian Securities Exchange.
PreveCeutical’s shares began trading on the CSE on an “ex-distribution” basis on May 23 (http://nnw.fm/Ll6nF), the day before the recording date for the stock split, which was set at a five new common shares for each one existing common share basis (http://nnw.fm/4nGst).
“We believe the Stock Split demonstrates the Company’s continued commitment to broaden its shareholder base and we anticipate that the Stock Split will make PreveCeutical’s securities more accessible to investors and enhance liquidity for shareholders,” CEO, president and board Chairman Stephen Van Deventer stated in announcing the dates.
PreveCeutical has five research and development programs under way to target type 2 diabetes and obesity, pain relief in a non-addicting manner, mild traumatic brain injury in athletes, cancer and various other ailments. PreveCeutical also sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the company’s website (www.CELLB9.com).
“When we’ve developed proof-of-concept on any of these projects, we intend to partner with other companies who will fund clinical trials,” Van Deventer said in a May interview with Financial Post (http://nnw.fm/sF6QS).
Chief Research Officer Dr. Harry Parekh, who leads the drug/gene delivery group at PreveCeutical’s University of Queensland’s research partner Pharmacy Australia Centre of Excellence (“PACE”), who developed the Sol-gel drug delivery mechanism employed by PreveCeutical as well as the technology that stabilizes molecules to make them viable as the company’s therapeutic products. Sol-gel refers to a water-soluble gel formulation that can be used to transport a drug into the body via the nasal cavity, for example, where it is expected to gain direct access to the brain and thus enhance its effectiveness.
“I’ve been courted by a number of entities to work on research projects in relation to my platforms and it’s fair to say that big pharma is not a good match for me,” Parekh told Financial Post, adding that PreveCeutical proved to be a good partner for him because “they understood my mission to translate technologies to medications in a moral and ethical fashion, with the goal of drastically reducing costs for end users … (while recognizing) the fundamental necessity of developing exploitable IP,” or intellectual property, for the benefit of investors.
One of PreveCeutical’s key efforts is to use Sol-gel to make cannabidiol (CBD) optimally bioavailable to patients dealing with pain, inflammation, seizures and neurological issues such as anxiety. CBD is a non-psychoactive product of the cannabis plant gaining wide use as a food additive in homeopathic consumables, but the Sol-gel formulation would allow the CBD to get to work without having to run through the potentially destructive gauntlet of the digestive system’s organs. PreveCeutical recently announced a non-disclosure agreement with a leading drug delivery device manufacturer to work with the Sol-gels (http://nnw.fm/PGsc7), as well as the second successful licensed international transport of dried cannabis materials for the PACE center’s research on the Sol-gels (http://nnw.fm/z3ZAn).
Grandview Research found that the market for alternative medicines was valued at $40.3 billion at the time of its study three years ago. The report found that 60 percent of the world’s population uses some type of traditional or non-conventional medicine, and a separate report by The National Center for Disease Control found that 20 percent of the United States’ population uses alternative therapies, as noted in a Crystal Equity Research Report on PreveCeutical (http://nnw.fm/nB5PL).
Crystal Equity’s report concluded that, “We expect 2018 will be a significant year for PreveCeutical Medical with numerous value-driving catalysts unfolding.”
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
